EICHOR
● Not Yet Recruiting
Compare the Efficacy and Safety of KH607 Tablets Versus Vortioxetine Hydrobromide Tablets in Adult Patients With Major Depressive Disorder
Condition: Major Depressive Disorder (MDD) · Sponsor: Chengdu Kanghong Pharmaceutical Group Co., Ltd.
About this study
This trial includes a short-term study and a long-term study. The short-term study is a multicenter, randomized, double-Blind, double-Dummy, Parallel-Controlled study with a 6-week duration. The long-term study is a withdrawal follow-up study; participants meeting relapse criteria may receive one cycle of KH607 Tablets treatment.
This description comes directly from the study's public registry record.
Talk to the study team
Gang Wang, Medical Doctor · 86-010-58303063 · adgangwang@163.com
Bing Bing Fu, Medical Doctor · 86-010-58303063 · fbbkidd@126.com
Always discuss trial participation with your own doctor first.
Locations (0)
| Locations not yet listed on the registry record. |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07741331